He stinks at third party support. Can't seem to hold the one he had. It has crippled the share price and continues to hang over us like a cloud. He has the credentials and education, it is the execution that is lacking. Yes, we have one heck of a pipeline, and yes we have diluted to death in just one year to give us a good looking balance sheet, but we need data and partnerships to really become noticed again. Right now ADXS seems to be the darling the pharma industry is touting, and for good reasons. I compare the two and see both as great plays, but I feel DR. Kim has squandered his opportunity and lost all momentum. Now, it is data and partnerships that will move the needle and get us noticed. We see a clear runway to 2018 and the street sees more dilution on the back of dilution and another RS in the que. As long as that is what he presents to the market we are a long, long way off going it alone. Rah, rah, rah.
I have said this many times here and this is a prime example. We have to have big pharma partners on some of our indications. I am sick of hearing we can go it alone rah, rah, rah. This seems to be the big #$%$ in the armor for Dr. Kim. Won't move the needle here with Geneone, you are right Alex. I really gave him more credit than he deserved in the financial area.
To generate some investment interest in this company. The shareholders can't do it by themselves. Everything I read here just indicates just how lax this management team is in trying to get investors interested. With the tax credit going forward and the Sony contract, the investment world should be taking notice and they're not. I think that is the point of the mirro7 rant, and many of us understand the frustration.
As a side note, I did add today and will hold this level for some time. I do believe Sony has to start getting their investment back sooner rather than later.
Sony is the key and Tokman is Tokman. Why would he consider shareholders at this point in our travels? Although it is up to our customers to announce there is nothing prohibiting MVIS from keeping us informed as to the progress being made on the laser front and the power and size fronts. I have always questioned Tokmans abilities and will never understand his reluctance to provide investors decent information to attract additional or new investment here. I also don't think he gives a dam as we approach the ASM and don't really look for anything we don't already know. Tokman is Tokman.
Well gentlemen, I did my best with the CES up dates as I received reports. I hope you will do the same and give us some of your deep thoughts on what you see and hear at the ASM.
Exactly, those are questions we deserve answers to or at least a better explanation from management. They don't mind asking for more shares for their performance. They should at least give us some insight as to why they deserve those perks with a little guidance on those issues you boys have brought up.
is needed to be seen by retail investors on the partnership side. You just can't keep handing the bills to the few who have kept this company afloat for the past several years. I have held bios in the past and they have done a great job of partnering and easing the load on investors. Dr. Kim stated partnerships were a prime goal of INO and yet he lost half of the only one we had. Today's post by VJ made it crystal clear that shareholders can expect more dilution by the company. For all the active indications we have going and the huge pipeline we have there has to be some relief that investors can see besides government subsidies. Without partnerships from big pharma, we can't even sell approved vaccines. It costs a fortune to develop a first rate sales staff and build from the ground up alone. It looks as if Mr. Hertels emal to VJ just opened some eyes as to just how long this is going to flounder with dilution always hanging over the company. Dr. Kim's failure to attract big pharma is his biggest flaw. The facebook, go it alone crowd, don't have a clue about the costs associated with going it alone. Just look at the number of posts VJ has under that heading. Tells a much bigger story.
I guess I'm old fashioned, I believe incentives should be performance based. When they can guide forward on earnings and profitability I can see a reason to award incentives. I cringe at awarding anything on "first and goal, shipping to the first of three" etc, etc. No disputing the fact that Sony is aboard and we are looking good and most of us are loaded right here, but I want to see him finish just once. Then we can talk about incentives for the team.
I had no difficulty voting no. They helped themselves to an 8 for 1 in 2012 as everybody knows and since then have given us a lot of hope and anguish. Things never looked better, but until they can forecast earnings and move the pps for us they can wait for additional dilution to fill their pockets. They have the votes to push it through as Bull2 says, but we retail, bill paying members of this exclusive club should let them know they have to start considering us. Even their timing on issues seems to discount shareholders over and over. Send a message.
Ten years here and we still have to guess at what management is doing while handing us the bills.